168 related articles for article (PubMed ID: 38495884)
1. Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future.
Singal AG; Yarchoan M; Yopp A; Sapisochin G; Pinato DJ; Pillai A
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38829199
[TBL] [Abstract][Full Text] [Related]
2. Breakthroughs in Hepatocellular Carcinoma Therapies.
Singal AG; Kudo M; Bruix J
Clin Gastroenterol Hepatol; 2023 Jul; 21(8):2135-2149. PubMed ID: 36813012
[TBL] [Abstract][Full Text] [Related]
3. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?
Boilève J; Guimas V; David A; Bailly C; Touchefeu Y
Curr Oncol; 2024 May; 31(6):3199-3211. PubMed ID: 38920726
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for advanced hepatocellular carcinoma: the potential of biologics.
Rossari F; Foti S; Camera S; Persano M; Casadei-Gardini A; Rimini M
Expert Opin Biol Ther; 2024 Jun; 24(6):455-470. PubMed ID: 38913107
[TBL] [Abstract][Full Text] [Related]
5. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
Li M; Bhoori S; Mehta N; Mazzaferro V
J Hepatol; 2024 Jun; ():. PubMed ID: 38848767
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
8. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
Whitham Z; Hsiehchen D
Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials.
Gamboa AC; Kooby DA; Maithel SK; Gamblin TC
J Surg Oncol; 2024 Jan; 129(1):63-70. PubMed ID: 38059310
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
[TBL] [Abstract][Full Text] [Related]
11. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
12. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
13. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B
NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
